MacroGenics Homepage
06:15 PM | May 23, 2013
Overview
Since its founding in 2000, MacroGenics has applied its world-class antibody capabilities to create life-changing medicines. The company’s innovative product candidates leverage its fully-integrated capabilities and its multiple, proprietary technology platforms.
Learn morePartnering
.png)
Jan. '13 - Strategic alliance with Gilead on four DARTs.
Sep. '12 - Collaboration with Servier on multiple oncology DARTs.
Dec. '11 - Collaboration with Servier on MGA271.
Oct. '10 - Global DART partnerships with Pfizer and Boehringer Ingelheim. Learn more
Home»News & Media
News & Media
Recent Press Releases
May 21, 2013 | Press ReleaseMacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer
January 07, 2013 | Press Release
MacroGenics and Gilead Sciences Enter Strategic Alliance to Develop and Commercialize Four DART™ Products
September 20, 2012 | Press Release
MacroGenics and Servier Enter Broad Strategic Alliance to Develop and Commercialize Three Anti-Cancer DART™ Products
> See all Press Releases
Recent News Articles
February 19, 2013 | BioWorldBispecific Antibodies Capturing Great Deal of Industry Interest
January 07, 2013 | Washington Business Journal
MacroGenics Could Get $1B Payday
January 07, 2013 | Dow Jones Business News
MacroGenics Strikes Another Deal; Gilead Alliance Could Yield More Than $1 Billion
> See all News
> Email Alerts: Stay on top of MacroGenics developments.
> Media Kit: Download corporate fact sheet and technology platform overview documents as well as corporate logos.